Fusion protein of retinol-binding protein and albumin domain III reduces liver fibrosis

Hongsik Lee1,†, Hyeyeun Jeong2,†, Sangeun Park2, Wonbaek Yoo2, Soyoung Choi2, Kyungmin Choi3, Min-Goo Lee3, Mihwa Lee4, DaeRyong Cha4, Young-Sik Kim5, Jeeyoung Han6, Wonkon Kim7, Sun-Hwa Park2 & Junseo Oh2,*

Abstract

Activated hepatic stellate cells (HSCs) play a key role in liver fibrosis, and inactivating HSCs has been considered a promising therapeutic approach. We previously showed that albumin and its derivative designed for stellate cell-targeting, retinol-binding protein–albumin domain III fusion protein (referred to as R-III), inactive cultured HSCs. Here, we investigated the mechanism of action of albumin/R-III in HSCs and examined the anti-fibrotic potential of R-III in vivo. R-III treatment and albumin expression downregulated retinoic acid (RA) signaling which was involved in HSC activation. RA receptor agonist and retinaldehyde dehydrogenase overexpression abolished the anti-fibrotic effect of R-III and albumin, respectively. R-III uptake into cultured HSCs was significantly decreased by siRNA-STRA6, and injected R-III was localized predominantly in HSCs in liver. Importantly, R-III administration reduced CCl4- and bile duct ligation-induced liver fibrosis. R-III also exhibited a preventive effect against CCl4-induced liver fibrosis. These findings suggest that the anti-fibrotic effect of albumin/R-III is, at least in part, mediated by downregulation of RA signaling and that R-III is a good candidate as a novel anti-fibrotic drug.

Keywords albumin; anti-fibrotic drug; fibrosis; hepatic stellate cell; retinoic acid

Subject Category Digestive System

DOI 10.15252/emmm.201404527 | Received 11 August 2014 | Revised 3 March 2015 | Accepted 9 March 2015 | Published online 11 April 2015

EMBO Mol Med (2015) 7: 819–830

Introduction

Liver fibrosis, characterized by excessive production and deposition of extracellular matrix (ECM) components, is a common response to chronic liver injury (Hernandez-Gea & Friedman, 2011). There is overwhelming evidence that activated hepatic stellate cells (HSCs) are major producers of fibrotic neomatrix, although additional cellular sources, such as portal myofibroblasts, bone marrow-derived cells, and epithelial-to-mesenchymal transition (EMT), have been reported (Forbes & Parola, 2011). In normal liver, HSCs remain quiescent and store approximately 70% of the body’s retinoid as retinyl ester in cytoplasmic lipid droplets. However, upon liver injury, quiescent HSCs become activated and transform into myofibroblast-like cells, which is invariably associated with loss of cytoplasmic vitamin A-containing lipid droplets, positive staining for α-smooth muscle actin (α-SMA), and greatly increased synthesis of ECM proteins (Friedman, 2008). Thus, HSCs are considered an attractive target for anti-fibrotic therapies (Li et al, 2008). Despite extensive investigations, there is, however, no effective therapy for liver fibrosis and end-stage cirrhosis, except for the removal of the causative agent and organ transplantation.

Retinoids (vitamin A and its metabolites) regulate multiple physiological activities, such as vision, morphogenesis, cell proliferation, and differentiation (Sporn et al, 1994). Vitamin A (retinol), acquired from the diet, is transported to the liver and taken up by hepatocytes as a chylomicron remnant. It has been suggested that retinol-binding protein (RBP) plays a role in the transfer of retinol from hepatocytes to HSCs via a RBP receptor STRA6 (Kawaguchi et al, 2007; Senoo et al, 2010). Upon HSC activation, some retinoid contents are oxidized to retinaldehyde and to retinoic acid (RA), a finding that is supported by the fact that all-trans retinoic acid level is increased in activated stellate cells compared with pre-activated stellate cells, whereas the contents of retinyl ester and retinol decrease (Okuno et al, 1999; Radaeva et al, 2007; D’Ambrosio et al, 2011). The diverse effects of retinoids are primarily mediated by two families of nuclear receptors, retinoic acid receptor (RAR) and retinoid X receptor (RXR) (Huang et al, 2014).
Albumin is an abundant multifunctional plasma protein synthesized primarily by liver cells (Evans, 2002). It is comprised of three homologous domains, each formed by two smaller subdomains (Curry et al., 1998). Crystallographic analysis has revealed that albumin has five high-affinity fatty acid binding sites, three of which are asymmetrically distributed in domain III (Curry et al., 1998; Simard et al., 2005). In a previous study, we showed that albumin is endogenously expressed in quiescent HSCs and that albumin expression inhibits HSC activation, which requires its intact fatty acid binding sites (Kim et al., 2009; Park et al., 2012). For therapeutic purposes, we constructed a recombiant fusion protein R-III, in which albumin domain III, retaining the anti-fibrotic activity, was fused to the C-terminus of RBP4. RBP4 was adopted for stellate cell-targeting delivery (Gjoen et al., 1987; Senoo et al., 1990). HPLC-purified R-III protein successfully entered and inactivated HSCs in vitro (Park et al., 2012). In this study, we demonstrated that R-III administration alleviated CCl₄- and bile duct ligation-induced liver fibrosis and that this anti-fibrotic effect was associated with HSC inactivation, at least in part, mediated by downregulation of RA signaling.

Results

Retinoic acid signaling is involved in HSC activation

The effects of exogenous retinoic acid (RA) on HSCs or liver fibrosis are controversial; several studies showed that RA inactivated HSCs and alleviated hepatic fibrosis (Wang et al., 2007; He et al., 2011), while other reports showed the opposite (Okuno et al., 1997, 2002). There is no clear answer for these conflicting results at the moment. Thus, we sought to examine the role of endogenous RA in HSC activation. HSCs were isolated from rat liver, and hepatocyte contamination was assessed by the expression of the hepatocyte-specific marker tyrosine aminotransferase (TAT) (Supplementary Fig S1). HSCs after passage 1 (HSCs-P1; activated HSCs) were incubated with citral, an inhibitor of retinaldehyde dehydrogenases (also known as aldehyde dehydrogenases ALDH) that irreversibly convert retinaldehyde to RA, and examined for changes. Citral treatment increased autofluorescent lipid droplets (Fig 1A) and decreased α-SMA levels (Fig 1B), a marker of HSC activation, which are the two most prominent features of inactivated HSCs. Citral treatment did not appear to be toxic as the cells grew normally after it was removed. We then examined the expression pattern of ALDH1A1 and ALDH1A2, responsible for RA synthesis in HSCs (Radaeva et al., 2007), during the culture activation of HSCs. Western blot analysis revealed that ALDH1A1 is expressed both in HSCs at day 3 after plating (HSCs-d3; pre-activated HSCs) and activated HSCs but relatively higher expression is found in HSCs-P1 (Fig 1C), as previously reported (Radaeva et al., 2007). Real-time PCR analysis, however, showed that ALDH1A1 mRNA levels gradually drop with culture passages (Fig 1D), suggesting that there are multiple pathways for the regulation of gene expression. On the other hand, ALDH1A2 mRNA and protein expression were prominently seen only in HSCs-P1. Next, we transfected HSCs-P1 with non-targeting siRNA or siRNA specific to ALDH1A1 and/or ALDH1A2. siRNA treatment suppressed ALDH1A1 protein expression (Fig 1E) and also reduced levels of all-trans RA and 13-cis-RA, two RA isomers found in HSCs (Okuno et al., 1999), although the relative abundance of isomers varied between different samples (Fig 1F).

Intriguingly, siRNA treatment also increased autofluorescent lipid droplets (Supplementary Fig S2) and decreased α-SMA levels and cell proliferation rate (Fig 1E and Supplementary Fig S3). Thus, suppression of both enzyme activity and expression of ALDH1A1 led to the inhibition of HSC activation, which agrees with the recent paper that suppression of alcohol dehydrogenase (ADH) 3 inhibits HSC activation (Yi et al., 2014). To examine directly whether RA signaling is involved in HSC activation, pre-activated HSCs-d3 were incubated with RAR antagonist (AGN193109) for 3 days and examined for phenotypic changes. RAR antagonist significantly inhibited HSC activation, which were reversed by addition of all-trans RA (Fig 1G and H). This indicates that RA plays a role in the process of HSC activation.

Downregulation of RA signaling may contribute to the anti-fibrotic effect of albumin

We previously showed that albumin expression and R-III (Supplementary Fig S4) treatment is accompanied with a reduction of cellular RA levels (Park et al., 2012). To examine whether the anti-fibrotic activity of albumin and R-III is attributed to decreased RA signaling, we carried out several experiments. First, HSCs-P1 were transfected with RARE-luciferase reporter and albumin expression vector. Luciferase assay revealed that albumin expression decreases...
Figure 1.

A

B

C

D

E

F

G

H

RBP–albumin fusion protein reduces liver fibrosis
Figure 2.
RA signaling by 70% (Fig 2A). A similar effect was observed with R-III treatment in a dose-dependent manner. Secondly, HSCs-P1 were transiently transfected with albumin expression vector in combination with plasmids encoding ALDH1A1 and ALDH1A2 and incubated in the presence of RA for 18 h. Albumin expression inactivated HSCs as previously reported (Kim et al., 2009), while co-expression of ALDH1A1 and ALDH1A2 abolished the albumin effect, in addition to increasing cellular RA levels (Fig 2B–D). Thirdly, HSCs-P1 were treated with R-III in the presence or absence of RAR agonist (AGN191183) for 18 h. R-III treatment inactivated HSCs with decreased α-SMA levels, but RAR agonist significantly reduced R-III effect (Fig 2E). This suggests that the anti-fibrotic effect of albumin and R-III is mediated, at least in part, by downregulation of RA signaling. Lastly, previous reports showed that albumin readily binds to retinoic acid, possibly at fatty acid binding sites (Smith et al., 1973; Belatik et al., 2012). To examine the possibility that albumin may reduce RA levels (bioavailability) via direct binding, we transfected HSCs-P1 with expression vector for mutant albumin, in which three high-affinity fatty acid binding sites (Arg410, Tyr411, and Lys525), located in domain III, were substituted with an alanine residue (Kragh-Hansen et al., 2006). Mutant albumin failed to induce HSC inactivation (Kim et al., 2009) and reduced RA levels only partially (Fig 2D). Thus, our findings suggest that albumin and R-III downregulate RA levels and its signaling probably via a direct binding, which may contribute to the inactivation of HSCs.

**STRA6 may be involved in the cellular uptake of R-III into HSCs**

Previous studies suggested that vitamin A bound to retinol-binding protein (RBP) enters HSCs via STRA6 (Kawaguchi et al., 2007; Senoo et al., 2010), but robust STRA6 expression was not reported in embryonic or adult liver tissue (Bouillet et al., 2010), but robust STRA6 expression was not reported in embryonic or adult liver tissue (Bouillet et al., 2010), while STRA6 was expressed in pre-activated and activated HSCs, but expression levels gradually drop with successive culture passages (Fig 3B). In a previous study, we showed that R-III enters and inactivates HSCs (Park et al., 2012). When HSCs at different stages of activation were incubated with His-tagged R-III for 30 min, Western blotting revealed that levels of R-III uptake paralleled STRA6 protein activation were incubated with His-tagged R-III for 30 min, Western blotting revealed that levels of R-III uptake paralleled STRA6 protein activation. The external surface of the liver in mineral oil/saline-treated control mice was smooth and glistening, whereas liver fibrosis was severe in CCl4/saline-treated mice, as evidenced by disruption of tissue architecture and large fibrous septa formation (Fig 4B). R-III significantly reduced histopathological alterations and collagen deposition. Hydroxyproline assays showed 35% reduction in collagen content by R-III, which was also confirmed by Western blot (Fig 5A and B). Intense immunostaining for α-SMA was found along the fibrotic septa around the central vein in CCl4/saline-treated livers, and R-III treatment considerably decreased α-SMA staining (Fig 5C), a finding that is consistent with our in vitro data indicating that R-III inactivates HSCs. Immunoreactivity with pro-fibrogenic mediator TGF-β was also significantly decreased with R-III treatment (Fig 6). Infiltration of F4/80-positive macrophages was increased in CCl4/saline-treated livers, whereas R-III treatment reduced F4/80 staining (Fig 6).

**Intravenously injected R-III localizes in hepatic stellate cells**

We then investigated the cellular distribution of injected, His-tagged R-III in liver by immunohistochemistry. In normal livers, desmin-positive, quiescent HSCs were distributed in the hepatic parenchyma within the perisinusoidal space, while desmin/α-SMA-positive, activated HSCs were primarily located in septal and portal areas in fibrotic livers (Fig 7). Importantly, His-tag staining extensively overlapped with desmin staining, although weak, non-specific

---

**Figure 2. Downregulation of RA signaling may contribute to the anti-fibrotic effect of albumin.**

A. Albumin and R-III downregulate RA signaling. HSCs-P1 were either transfected with RARE Cignal reporter and expression plasmid containing vehicle or albumin (left panel) or treated with R-III (25–250 nM) after transfection with RARE Cignal reporter (right panel). After 36 h, the transfected cells were harvested for luciferase assay. Renilla luciferase activity was normalized to firefly luciferase activity. Ratios were normalized against the cells transfected with vehicle plasmid. **P-value, two-sample t-test (n = 9) (compared to control), albumin: 0.0037, R-III 125 nM: 0.0032.

B. Phenotypic changes of HSCs by the expression of albumin and/or ALDH1A1. HSCs-P1 were transfected with plasmids encoding albumin, ALDH1A1, and ALDH1A2, either individually or in combination, and incubated in the presence of all-trans retinoic acid (50 nM) for 18 h. Cells were analyzed by oil red O staining. Scale bar, 20 μm.

C. Western blot analysis of cell lysates from albumin- and/or ALDH1A1-transfected HSCs as in (D). **P = 0.002, paired t-test (n = 3) (albumin compared to control).

D. Reverse-phase HPLC analysis of whole-cell lysates from albumin- and/or ALDH1A1-transfected HSCs as in (B). **P = 0.002, paired t-test (n = 3) (R-III compared to control). The separating lines demarcate bands that come from non-consecutive lanes of the same gel.

E. RAR agonist counteracts R-III action. HSCs-P1 were treated with His-tagged R-III (final concentration, 0.15 μM) in the presence or absence of RAR agonist (AGN191183, 1 μM) for 18 h and analyzed by Western blotting. **P = 0.0024, paired t-test (n = 3) (R-III compared to control). The separating lines demarcate bands that come from non-consecutive lanes of the same gel.

Source data are available online for this figure.
Figure 3. STRA6 may be involved in the cellular uptake of R-III into HSCs.

A Protein expression of STRA6 during the culture activation of HSCs. Cell lysates were prepared from HSCs at 3 days after plating (HSCs-3d), and from HSCs after passage 1 (P1), 2 (P2), and 3 (P3), and analyzed by Western blotting. Lysates from NIH3T3 cells were used as a negative control. The separating lines demarcate bands that come from non-consecutive lanes of the same gel.

B Real-time PCR analysis for the expression level of STRA6 during the culture activation of HSCs. The PCR data are expressed as the percentage of HSCs-3d. **P-value, paired t-test (n = 3) (compared to HSCs-3d), HSCs-P1: 0.002, HSCs-P2: 0.0022.

C R-III uptake parallels STRA6 level. HSCs at different stages of activation were incubated with His-tagged R-III (final concentration, 0.15 μM) for 30 min, washed, and subjected to Western blotting for R-III uptake.

D STRA6-mediated uptake of R-III. HSCs-P1 were transfected with non-targeting siRNA or one of the two different STRA6-specific siRNAs, and after 48 h, cells were incubated with R-III for 30 min and analyzed by Western blotting.

Source data are available online for this figure.

Figure 4. Therapeutic effect of R-III on CCl4-induced liver fibrosis.

A Representative macroscopic pictures of livers from control and CCl4-, CCl4/albumin-, CCl4/RBP-, and CCl4/R-III-treated mice.

B Liver sections were stained with H&E and Sirius red, and also subjected to immunohistochemistry for type I collagen. Scale bar, 200 μm.

EMBO Molecular Medicine Vol 7 | No 6 | 2015

RBP–albumin fusion protein reduces liver fibrosis

Hongseok Lee et al

824

Published online: April 11, 2015

© 2015 The Authors
signal was also detected in parenchymal cells. This in vivo finding, along with early in vitro data (Fig 3D), suggests that the RBP domain successfully targeted R-III to hepatic stellate cells.

R-III slows the onset of CCl₄-induced liver fibrosis

To examine whether R-III has a preventive effect on CCl₄-induced liver fibrosis, mice were treated with CCl₄ and R-III on different days three times per week over a period of 7 weeks (Supplementary Fig S6). Sirius red staining of liver sections showed that R-III treatment markedly reduced collagen deposition (Fig 8A). Collagen content was reduced by 45% in the R-III-treated group, as measured using hydroxyproline assays (Fig 8B).

R-III reduces BDL-induced liver fibrosis

Mice underwent BDL and were daily administered with R-III (1, 5 or 10μg) from 2 to 3 weeks of BDL (Supplementary Fig S7). R-III treatment reduced cholestatic liver fibrosis (Fig 9A) and reduced collagen content by up to 45% (Fig 9B).
HSCs are considered an attractive target for anti-fibrotic therapies. Several previous reports aimed to inactivate HSCs and reduce liver fibrosis, but no effective therapy for treating liver fibrosis is currently available, mainly due to our incomplete understanding of the molecular mechanism underlying the activation of HSCs and the lack of target specificity of candidate drugs (Ghiassi-Nejad & Friedman, 2008). We have previously showed that forced expression of albumin inactivates stellate cells in vitro (Kim et al., 2009; Park et al., 2012), and developed the recombinant fusion protein R-III, in which albumin domain III is fused to the C-terminus of retinol-binding protein for stellate cell-specific delivery (Choi et al., 2012; Park et al., 2012). Treatment of HPLC-purified R-III inactivated cultured HSCs as seen by albumin expression.

Our in vitro experiment in this study showed that R-III uptake into HSCs is markedly affected by siRNA-STRA6. When injected via tail vein, R-III was predominantly delivered to stellate cells in the liver, indicating that RBP was successfully adopted as a targeting moiety. More importantly, R-III significantly attenuated CCl4-induced liver fibrosis with a concomitant reduction of \( \alpha \)-SMA-positive cells. This anti-fibrotic effect was not, however, observed with either albumin or RBP (Fig 4). R-III also exhibited anti-fibrotic effect on bile duct ligation-induced liver fibrosis. These findings show that R-III is a novel anti-fibrotic drug candidate targeting stellate cells.

Upon stellate cell activation, cytoplasmic lipid droplets collapse and a portion of the retinoid contents are likely released and metabolized. The kinetics of protein expression of ALDH1A1 and ALDH1A2, responsible for retinoic acid (RA) synthesis in HSCs, coincided with RA production; their levels peaked as HSCs freshly isolated from rat liver reached confluence and were passaged (Fig 1). The role of retinoids in HSC activation has been proposed, but previous reports about the effects of exogenous retinoids on HSCs and fibrogenesis were contradictory; several studies showed...
the inhibitory effect of RA on hepatic fibrosis (Wang et al., 2007; He et al., 2011), while other reports showed the opposite (Okuno et al., 1997, 2002). There is no clear answer for this controversy at the moment, although several possible explanations were proposed (Zhou et al., 2012). Thus, we sought to evaluate the role of endogenous RA in HSC activation. When enzyme activity or protein expression of ALDH1A1 and ALDH1A2 was suppressed, HSCs underwent cell inactivation with observations of increased lipid droplets and decreases in α-SMA and RA levels. Furthermore, RAR antagonist inhibited HSC activation, indicating that RA signaling plays a role in stellate cell activation.

Albumin binds a wide variety of hydrophobic ligands. Binding of fatty acids to albumin has been extensively studied, and multiple binding sites on albumin have been located (Curry et al., 1998; Simard et al., 2005; Kragh-Hansen et al., 2006). Biophysical studies also showed that albumin readily binds to retinoic acid, possibly at its fatty acid binding sites (Smith et al., 1973; Belatik et al., 2012). This finding agrees with those of a recent report that albumin sequesters RA, preventing podocyte differentiation (Peired et al., 2013). It is also supported by our previous finding that both albumin expression and R-III treatment markedly decrease cellular RA levels in HSCs (Park et al., 2012). Thus, it is possible to reason that the anti-fibrotic effect of albumin and R-III is attributed to downregulation of RA signaling which is involved in the process of HSC activation. Our study showed that albumin expression and R-III treatment indeed lead to downregulation of RA signaling in HSCs (Fig 2A) and that their anti-fibrotic effects are abolished by ALDH1A1 overexpression and RA receptor agonist, respectively (Fig 2B and E). Furthermore, studies of mutant albumin R410A/Y411A/K525A, which fails to induce HSC inactivation (Kim et al., 2009) and modulates RA levels only partially (Fig 2D), strongly suggest a direct interaction between RA and albumin (fatty acid binding sites). Therefore, these findings suggest that downregulation of RA signaling by removal of RA may contribute to the anti-fibrotic action of albumin and R-III in HSCs.

Our study showed that there is an increase in cytoplasmic lipid droplets in citral-treated, siRNA-ALDH1A-transfected, and albumin-transfected HSCs-P1, as assessed by oil red O staining. We examined whether retinyl palmitate levels in these inactivated cells were increased by reverse-phase HPLC but found no significant differences. The reason may be that the detection method is not sensitive enough to detect small change. In our experiments, retinol and palmitate were not added to the culture media. Alternatively, the reappearance of lipid droplets may not accompany new synthesis of retinyl esters. At present, we have no clear answer for this. There was, however, an increase in autofluorescence (Fig 1A and Supplementary Fig S2), indicating that lipid droplets likely contain retinoids. Further studies are needed to elucidate the detailed mechanisms of albumin/R-III action and HSC activation.

The HSC population in a healthy, uninjured liver shows heterogeneity in levels of HSC activation markers and retinyl ester (D’Ambrosio et al., 2011). Thus, it is likely that one subset of HSCs in normal liver may have elevated STRA6 levels and be ready for vitamin A uptake, while the majority of HSCs have abundant perinuclear lipid droplets and may not need to maintain high STRA6 level. Interestingly, it was observed that STRA6 protein level was not correlated with mRNA level in HSCs at day 3 after plating (pre-activated HSCs) (Fig 3A and B). Although further study is required to elucidate the detailed mechanisms underlying these phenomena, protein degradation is a likely explanation.

Retinoid-storing stellate cells also exist in extrahepatic organs such as pancreas, kidney, spleen, intestine, and lung (Nagy et al., 1997). These cells show striking similarities in morphology and perivascular location, which suggests that activated stellate cells may contribute to the myofibroblast cells seen in the fibrotic extrahepatic tissues (Erkan et al., 2012). As intravenously injected R-III is detected also in extrahepatic organs such as brain, lung, spleen, pancreas, kidney, and intestine (Choi et al., 2012), we have examined...
whether R-III reduces renal and pulmonary fibrosis (manuscript in preparation). We also found that R-III has a plasma half-life of ~20 h (Supplementary Fig S8) and that mice showed no apparent side effects after receiving R-III (10 μg, intravenous injection once daily for 7 days).

In this study, we demonstrated that the fusion protein R-III alleviated CCl4- and bile duct ligation-induced liver fibrosis by inducing HSC inactivation. Our finding may provide a new approach to treating fibrotic diseases in different tissues.

Materials and Methods

Animals

Male Sprague-Dawley rats of 6–8 weeks of age and male BALB/c mice of 6–8 weeks were purchased from Orient (Charles River Korea, Seoul, Korea). Animals were fed a commercial diet R03-10 (Safe, Augy, France) and maintained under temperature-, humidity-, and light-controlled conditions. Animal experiments were approved by our institutional review board and complied with the Guide for the Care and Use of Laboratory Animals.

Hepatic stellate cell isolation and culture

Rats were anesthetized intraperitoneally with sodium thiopental, and primary HSCs were isolated as described previously (Langer et al., 2008) and cultured in DMEM supplemented with 10% fetal bovine serum. The purity of stellate cells was >90% as assessed by the presence of cytoplasmic lipid droplets and Western blotting using anti-tyrosine aminotransferase antibody. The isolated cells reach confluence after 5–7 days in culture and subcultured in a threefold dilution.

Western blot analysis

Electrophoresis and immunoblotting were performed as described (Kim et al., 2009). Primary antibodies used were STRA6 (Prosci #46-715, Poway, CA, USA), α-SMA (Sigma-Aldrich #A2547, St. Louis, MO, USA), albumin (Bethyl Laboratories #A110-134A, Montgomery, TX, USA), His-tag (AB Frontier #LF-MA-20209 Seoul, Korea), type I collagen (Callbiochem #234168, San Diego, CA, USA), ALDH1A1 (Abcam #ab52492, Cambridge, UK), ALDH1A2 (Abcam #ab156019), and α-tubulin (Cell Signaling Technology #2125, Beverly, MA, USA).

Analysis of gene expression using real-time PCR

cDNA was synthesized from total RNA, and real-time PCR was performed using LightCycler-FastStart DNA Master SYBR Green 1 (Roche, Mannheim, Germany) with gene-specific primers (Supplementary Table S1). To control for variations in the reactions, PCR products were normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression.

Purification of (His)6-tagged R-III fusion protein

Expression vector for mouse R-III and the high producing, stably transected 293 cell lines were prepared as described previously (Choi et al., 2012). For the purification of R-III, conditioned medium was prepared from transfected 293 cells grown in serum-free medium for 4 days, fractionated with ammonium sulfate (55%), and then subjected to a His Trap affinity column. The sample was further purified using Resource Q. Purified protein was dialyzed against deionized water, freeze-dried, and dissolved in saline solution. The purity of R-III is >95%, as determined by SDS–PAGE and protein staining.

Transfection and si-RNAs

HSCs were transiently transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and analyzed after 24 h. Knockdown of STRA6, ALDH1A1, or ALDH1A2 was performed using specific siRNA duplexes sets (Supplementary Table S2) from Bioneer (Daejeon, Korea).

Luciferase assay

HSCs were transiently transfected with a combination of RARE Cignal report (Qiagen, Germantown, MD, USA), including inducible transcription factor responsive construct and constitutively expressing Renilla luciferase construct, and the respective vector (pcDNA3.1 or pcDNA3.1-albumin). After 36 h, the luciferase assay was performed using Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. The ratio between firefly and Renilla luciferase was used to normalize the transfection efficiency. Quantification was performed on three independent experiments executed in triplicate.

Liver fibrosis induced by CCl4 or BDL

For CCl4-induced liver fibrosis study, BALB/c mice were treated with CCl4 (1 ml/kg body weight; 1:1 dilution with mineral oil) or mineral oil as a control by intraperitoneal (i.p.) injection three times.
per week for 7 weeks. For the determination of therapeutic effects of R-III, a total of 20 CCl₄-treated mice were randomly divided into four groups (each group = 5 mice); mice were administered via tail vein injection (without anesthesia) with saline, albumin (10 μg), RBP (5 μg), or R-III (10 μg) every day during the last 2 weeks of CCl₄ treatment (Supplementary Fig S5). For the assessment of preventive effects of R-III, a total of 10 CCl₄-treated mice were randomly divided into two groups (five mice per group) and administered with saline or R-III (Supplementary Fig S6). Three to five mineral/saline-treated mice were used as normal controls for each experiment. For the study of liver fibrosis induced by BDL, mice were anesthetized intraperitoneally by ketamine and xylazine. After midline laparotomy, the common bile duct was double-ligated and transected between the ligatures. The sham operation was performed similarly without BDL. After BDL for 7 days, R-III (0, 1, 5, or 10 μg) was daily administered for another 2 weeks (five mice per group) (Supplementary Fig S7). All experiments were repeated twice.

**Immunohistochemical analysis**

After routine processing, sections (5 μm thick) of formalin-fixed, paraffin-embedded liver tissues were prepared and stained with H&E for histological analysis or Sirius red for collagen deposition. Tissue sections were also stained immunohistochemically with the following antibodies: desmin (Dako #M0760, Carpinteria, CA, USA), α-SMA (Abcam #ab32575), His-tag (Abcam #ab84162), TGF-β (Santa Cruz #sc146, Santa Cruz, CA, USA), and F4/80 (Serotec #MCA497, Kidlington, UK).

**Hydroxyproline measurement**

Liver hydroxyproline levels were measured following the manufacturer’s protocol (Sigma-Aldrich). Briefly, liver tissue was homogenized in distilled water and mixed with an equal volume of concentrated hydrochloric acid (~12 N HCl), and the homogenates were incubated at 120°C for 3 h. After hydrolysis, the samples were oxidized with Chloramine T (Sigma-Aldrich), followed by enzymatic reaction with 4-dimethylaminobenzaldehyde (DMAB) solution. Sample absorbance was measured at 560 nm in duplicate. Hydroxyproline content was expressed at nanogram of hydroxyproline per milligram liver.

**Oil red O staining and autofluorescence**

HSCs were stained with Oil red O to visualize lipid droplets, essentially as described previously (Kim et al, 2009). Oil red O was diluted in triethyl phosphate instead of isopropanol. The fast-fading vitamin A-specific autofluorescence was observed with light of 330–360 nm (UV) laser.

**RP-HPLC**

Cells were quantified and extracted as described (Merris et al, 2002). Reverse-phase chromatography (RP-HPLC) was carried out on an AKTA Explorer HPLC system (GE Healthcare Life Sciences, Piscataway, NJ, USA). The chromatographic conditions were as previously described (Radaeva et al, 2007).

**Statistical analysis**

Results are expressed as mean ± standard deviation (SD). Paired t-test or two-sample t-test were performed where appropriate. Comparisons were considered significant at P < 0.05.

**Supplementary information**

For this article is available online: http://embomolmed.embobpress.org

**Acknowledgements**

We thank Dr. William G. Stetzel-Stevenson for encouragement and discussion. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012R1A1A204349).

**Author contributions**

HL, HJ, and JO designed the experiments; SP, HJ, WY, SC, KC, ML, YK, JH, and WK performed the experiments; MGL, HL, DC, YK, and JO analyzed the data; and SP, HJ, and JO wrote and reviewed the paper.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**References**

Belatik A, Hotchandani S, Bariyanga J, Tajmir-Riahi HA (2012) Binding sites of retinol and retinoic acid with serum albumins. Eur J Med Chem 48: 114–123

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.

Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (2007). EMBO Molecular Medicine 360 nm (UV) laser.
He H, Mennone A, Boyer JL, Cai SY (2011) Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic stellate cells. *Hepatology* 53: 548 – 557

Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. *Annu Rev Pathol* 6: 425 – 456

Huang P, Chandra V, Rastinejad F (2014) Retinoic acid actions through mammalian nuclear receptors. *Chem Rev* 114: 233 – 254

Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P, Wiita P, Bok D, Sun H (2007) A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. *Science* 315: 820 – 825

Kim N, Yoo W, Lee J, Kim H, Lee H, Kim YS, Kim DU, Oh J (2009) Formation of vitamin A lipid droplets in pancreatic stellate cells requires albumin. *Cutan Pharmacol* 58: 1382 – 1390

Kragh-Hansen U, Watanabe H, Nakajou K, Iwao Y, Otagiri M (2007) Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. *Hepatology* 47: 1983 – 1993

Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, Katusic ZS, Gores GJ, Shah VH (2008) Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. *Hepatology* 47: 1983 – 1993

Merris V, Van ME, De Wasch K, Burvenich C (2002) Simple quantification of endogenous retinoids in bovine serum by high-performance liquid chromatography – diode-array detection. *Anal Chim Acta* 468: 237 – 244

Nagy NE, Holven KB, Roos N, Senoo H, Kojima H, Norum KR, Blomhoff R (1997) Storage of vitamin A in extrahepatic stellate cells in normal rats. *J Lipid Res* 38: 645 – 658

Okuno M, Moriwaki H, Imai S, Muto Y, Kawada N, Suzuki Y, Kojima S (1997) Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. *Hepatology* 26: 913 – 921

Okuno M, Sato T, Kitamoto T, Imai S, Kawada N, Suzuki Y, Yoshimura H, Moriwaki H, Onuki K, Masushige S et al (1999) Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo. *J Hepatol* 30: 1073 – 1080

Okuno M, Kojima S, Akita K, Matsushima-Nishiwaki R, Adachi S, Sano T, Takano Y, Takai K, Obara A, Yasuda I et al (2002) Retinoids in liver fibrosis and cancer. *Front Biosci* 7: d204 – d218

Park S, Choi S, Lee MG, Lim C, Oh J (2012) Retinol binding protein-albumin domain III fusion protein deactivates hepatic stellate cells. *Mol Cells* 34: S17 – S22

Peith A, Angelotti ML, Ronconi E, la Marca G, Mazzinghi B, Sisti A, Lombardi D, Giocaliare E, Della Bona M, Villanelli F et al (2013) Proteinuria impairs podocyte regeneration by sequestering retinoic acid. *J Am Soc Nephrol* 24: 1756 – 1768

Radaeva S, Wang L, Radaev S, Jeong WI, Park O, Gao B (2007) Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. *Am J Physiol Gastrointest Liver Physiol* 293: C809 – C816

Senoo H, Shibata E, Nilsson A, Kindberg GM, Berg T, Roos N, Norum KR, Blomhoff R (1990) Internalization of retinol-binding protein in parenchymal and stellate cells of rat liver. *J Lipid Res* 31: 1229 – 1239

Senoo H, Yoshikawa K, Morii M, Miura M, Imai K, Mezaki Y (2010) Hepatic stellate cell (vitamin A-storing cell) and its relative–past, present and future. *Cell Biol Int* 34: 1247 – 1272

Simard JR, Zunszain PA, Ha CE, Yang JS, Bhagavan NV, Petitpas I, Curry S, Hamilton JA (2005) Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. *Proc Natl Acad Sci U S A* 102: 17958 – 17963

Smith JE, Milch PO, Muto Y, Goodman DS (1973) The plasma transport and metabolism of retinoic acid in the rat. *Biochem J* 132: 821 – 827

Sporn MB, Roberts AB, Goodman DS (1994) The *Retinoids: Biology, Chemistry, and Medicine*. 2nd edn. New York: Raven Press

Wang L, Potter JJ, Rennie-Tankersley L, Novitskiy G, Sipes J, Mezey E (2007) Effects of retinoic acid on the development of liver fibrosis produced by carbon tetrachloride in mice. *Biochim Biophys Acta* 1772: 66 – 71

Yi HS, Lee YS, Byun JS, Seo W, Jeong JM, Park O, Duester G, Haseba T, Kim SC, Park KG et al (2014) Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice. *Hepatology* 60: 1044 – 1053

Zhou TB, Drummen GP, Qin YH (2012) The controversial role of retinoic Acid in fibrotic diseases: analysis of involved signaling pathways. *Int J Mol Sci* 14: 226 – 243

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.